Assessment of tumor response to tyrosine kinase inhibitors

Frontiers in Bioscience

Volumn 16, Issue 6, 2011, Pages 1996-2007

  Lowery, Amanda ^a   Han, Zhaozhong ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Biomarkers; Functional imaging; Imaging; Molecular imaging; Receptor tyrosine kinase; Response To therapy; Review; Tyrosine kinase inhibitors

Indexed keywords

PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; TUMOR MARKER;

DIAGNOSTIC IMAGING; DRUG ANTAGONISM; HUMAN; METABOLISM; METHODOLOGY; NEOPLASM; PATHOLOGY; REVIEW; TREATMENT OUTCOME;

DIAGNOSTIC IMAGING; HUMANS; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 79959725684     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/3836     Document Type: Review

References (62)

1. Marcus, C. D., V. Ladam-Marcus, C. Cucu, O. Bouche, L. Lucas & C. Hoeffel: Imaging techniques to evaluate the response to treatment in oncology: current standards and perspectives. Crit Rev Oncol Hematol, 72, 217-38 (2009)
2. Willmann, J. K., N. van Bruggen, L. M. Dinkelborg & S. S. Gambhir: Molecular imaging in drug development. Nat Rev Drug Discov, 7, 591-607 (2008) (Pubitemid 351927724)
3. Gschwind, A., O. M. Fischer & A. Ullrich: The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer, 4, 361-70 (2004) (Pubitemid 38579482)
4. Mishani, E., G. Abourbeh, M. Eiblmaier & C. J. Anderson: Imaging of EGFR and EGFR tyrosine kinase overexpressionin tumors by nuclear medicine modalities. Curr Pharm Des, 14, 2983-98 (2008)
5. Krause, D. S. & R. A. van Etten: Tyrosine kinases as targets for cancer therapy. N Engl J Med, 353, 172-87 (2005) (Pubitemid 41058349)
6. Di Renzo, M. F., M. Olivero, A. Giacomini, H. Porte, E. Chastre, L. Mirossay, B. Nordlinger, S. Bretti, S. Bottardi, S. Giordano & et al.: Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer. Clin Cancer Res, 1, 147-54 (1995)
7. Ma, P. C., T. Kijima, G. Maulik, E. A. Fox, M. Sattler, J. D. Griffin, B. E. Johnson & R. Salgia: c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res, 63, 6272-81 (2003) (Pubitemid 37255174)
8. Chu, C. T., K. D. Everiss, C. J. Wikstrand, S. K. Batra, H. J. Kung & D. D. Bigner: Receptor dimerization is not a factor in the signalling activity of a transforming variant epidermal growth factor receptor (EGFRvIII) Biochem J, 324 ( Pt 3), 855-61 (1997) (Pubitemid 27285544)
9. Li, E., M. You & K. Hristova: FGFR3 Dimer Stabilization Due to a Single Amino Acid Pathogenic Mutation Journal of Molecular Biology, 356, 600-612 (2006) (Pubitemid 43139323)
10. Gomez, A., C. Wellbrock, H. Gutbrod, N. Dimitrijevic & M. Schartl: Ligand-independent dimerization and activation of the oncogenic Xmrk receptor by two mutations in the extracellular domain. J Biol Chem, 276, 3333-40 (2001)
11. Hirsch, F. R., M. Varella-Garcia & F. Cappuzzo: Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer. Oncogene, 28 Suppl 1, S32-7 (2009)
12. Mitsudomi, T. & Y. Yatabe: Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. Febs J, 277, 301-8 (2009)
13. Grant, S. K.: Therapeutic protein kinase inhibitors. Cell Mol Life Sci, 66, 1163-77 (2009)
14. Steeghs, N., J. W. Nortier & H. Gelderblom: Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update of recent developments. Ann Surg Oncol, 14, 942-53 (2007) (Pubitemid 46175346)
15. Le Tourneau, C., L. Vidal & L. L. Siu: Progress and challenges in the identification of biomarkers for EGFR and VEGFR targeting anticancer agents. Drug Resist Updat, 11, 99-109 (2008)
16. Bonomi, P. D., L. Buckingham & J. Coon: Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors. Clin Cancer Res, 13, s4606-12 (2007)
17. Garassino, M. C., K. Borgonovo, A. Rossi, A. Mancuso, O. Martelli, A. Tinazzi, S. Di Cosimo, N. La Verde, P. Sburlati, C. Bianchi, G. Farina & V. Torri: Biological and clinical features in predicting efficacy of epidermal growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis. Anticancer Res, 29, 2691-701 (2009)
18. Hormigo, A., P. H. Gutin & S. Rafii: Tracking normalization of brain tumor vasculature by magnetic imaging and proangiogenic biomarkers. Cancer Cell, 11, 6-8 (2007) (Pubitemid 46054523)
19. Paez, J. G., P. A. Janne, J. C. Lee, S. Tracy, H. Greulich, S. Gabriel, P. Herman, F. J. Kaye, N. Lindeman, T. J. Boggon, K. Naoki, H. Sasaki, Y. Fujii, M. J. Eck, W. R. Sellers, B. E. Johnson & M. Meyerson: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, 304, 1497-500 (2004) (Pubitemid 38720929)
20. Ono, M. & M. Kuwano: Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs. Clin Cancer Res, 12, 7242-51 (2006) (Pubitemid 46095395)
21. Geng, L., E. T. Shinohara, D. Kim, J. Tan, K. Osusky, Y. Shyr & D. E. Hallahan: STI571 (Gleevec) improves tumor growth delay and survival in irradiated mouse models of glioblastoma. Int J Radiat Oncol Biol Phys, 64, 263-71 (2006) (Pubitemid 41831236)
22. Shah, C., T. W. Miller, S. K. Wyatt, E. T. McKinley, M. G. Olivares, V. Sanchez, D. D. Nolting, J. R. Buck, P. Zhao, M. S. Ansari, R. M. Baldwin, J. C. Gore, R. Schiff, C. L. Arteaga & H. C. Manning: Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer. Clin Cancer Res, 15, 4712-21 (2009)
23. Huamani, J., C. Willey, D. Thotala, K. J. Niermann, M. Reyzer, L. Leavitt, C. Jones, A. Fleishcher, R. Caprioli, D. E. Hallahan & D. W. Kim: Differential efficacy of combined therapy with radiation and AEE788 in high and low EGFRexpressing androgen-independent prostate tumor models. Int J Radiat Oncol Biol Phys, 71, 237-46 (2008)
24. Cuneo, K. C., L. Geng, A. Fu, D. Orton, D. E. Hallahan &A. B. Chakravarthy: SU11248 (sunitinib) sensitizes pancreatic cancer to the cytotoxic effects of ionizing radiation. Int J Radiat Oncol Biol Phys, 71, 873-9 (2008) (Pubitemid 351749533)
25. Stoeckli, M., P. Chaurand, D. E. Hallahan & R. M. Caprioli: Imaging mass spectrometry: a new technology for the analysis of protein expression in mammalian tissues. Nat Med, 7, 493-6 (2001) (Pubitemid 32298555)
26. Meistermann, H., J. L. Norris, H. R. Aerni, D. S. ornett, A. Friedlein, A. R. Erskine, A. Augustin, M. C. De Vera Mudry, S. Ruepp, L. Suter, H. Langen, R. M. Caprioli & A. Ducret: Biomarker discovery by imaging mass spectrometry: transthyretin is a biomarker for gentamicin-induced nephrotoxicity in rat. Mol Cell Proteomics, 5, 1876-86 (2006) (Pubitemid 44688196)
27. Stauber, J., R. Lemaire, J. Franck, D. Bonnel, D. Croix, R. Day, M. Wisztorski, I. Fournier & M. Salzet: MALDI imaging of formalin-fixed paraffin-embedded tissues: application to model animals of Parkinsondisease for biomarker hunting. J Proteome Res, 7, 969-78 (2008)
28. Taguchi, F., B. Solomon, V. Gregorc, H. Roder, R. Gray, K. Kasahara, M. Nishio, J. Brahmer, A. Spreafico, V. Ludovini, P. P. Massion, R. Dziadziuszko, J. Schiller, J. Grigorieva, M. Tsypin, S. W. Hunsucker, R. Caprioli, M. W. Duncan, F. R. Hirsch, P. A. Bunn, Jr. & D. P. Carbone: Mass spectrometry to classify non-smallcell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. J Natl Cancer Inst, 99, 838-46 (2007)
29. Haouala, A., B. Zanolari, B. Rochat, M. Montemurro, K. Zaman, M. A. Duchosal, H. B. Ris, S. Leyvraz, N. Widmer & L. A. Decosterd: Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci, 877, 1982-96 (2009)
30. Goon, P. K., G. Y. Lip, C. J. Boos, P. S. Stonelake & A. D. Blann: Circulating endothelial cells, endothelial progenitor cells, and endothelial microparticles in cancer. Neoplasia, 8, 79-88 (2006)
31. Norden-Zfoni, A., J. Desai, J. Manola, P. Beaudry, J. Force, R. Maki, J. Folkman, C. Bello, C. Baum, S. E. DePrimo, D. R. Shalinsky, G. D. Demetri & J. V. Heymach: Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clin Cancer Res, 13, 2643-50 (2007) (Pubitemid 46788031)
32. Batchelor, T. T., A. G. Sorensen, E. d. Tomaso, Wei-Ting Zhang, D. G. Duda, K. S. Cohen, K. R. Kozak, D. P. Cahill, P.-J. Chen, M. Zhu, M. Ancukiewicz, M. M. Mrugala, S. Plotkin, J. Drappatz, D. N. Louis, P. Ivy, D. T. Scadden, T. Benner, J. S. Loeffler, P. Y. Wen & R. K. Jain: AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma Patients. Cancer Cell, 11, 83-95 (2007) (Pubitemid 46075199)
33. Jain, R. K., D. G. Duda, C. G. Willett, D. V. Sahani, A. X. Zhu, J. S. Loeffler, T. T. Batchelor & A. G. Sorensen: Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol, 6, 327-38 (2009)
34. Koyanagi, K., A. J. Bilchik, S. Saha, R. R. Turner, D. Wiese, M. McCarter, P. Shen, L. Deacon, D. Elashoff & D. S. Hoon: Prognostic relevance of occult nodal micrometastases and circulating tumor cells in colorectal cancer in a prospective multicenter trial. Clin Cancer Res, 14, 7391-6 (2008)
35. Tveito, S., G. M. Maelandsmo, H. K. Hoifodt, H. Rasmussen & O. Fodstad: Specific isolation of disseminated cancer cells: a new method permitting sensitive detection of target molecules of diagnostic and therapeutic value. Clin Exp Metastasis, 24, 317-27 (2007) (Pubitemid 47124933)
36. Vroling, L., J. S. Lind, R. R. de Haas, H. M. Verheul, V. W. van Hinsbergh, H. J. Broxterman & E. F. Smit: CD133+ circulating haematopoietic progenitor cells predict for response to sorafenib plus erlotinib in non-small cell lung cancer patients. Br J Cancer, 102, 268-75 (2010)
37. Brindle, K.: New approaches for imaging tumour responses to treatment. Nat Rev Cancer, 8, 94-107 (2008) (Pubitemid 351161320)
38. Goerres, G. W., R. Stupp, G. Barghouth, T. F. Hany, B. Pestalozzi, E. Dizendorf, P. Schnyder, F. Luthi, G. K. von Schulthess & S. Leyvraz: The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate. Eur J Nucl Med Mol Imaging, 32, 153-62 (2005) (Pubitemid 40248485)
39. Weissleder, R.: Scaling down imaging: molecular mapping of cancer in mice. Nat Rev Cancer, 2, 11-8 (2002) (Pubitemid 37328803)
40. Aliu, S. O., L. J. Wilmes, M. M. Moasser, B. C. Hann, K. L. Li, D. Wang & N. M. Hylton: MRI methods for evaluating the effects of tyrosine kinase inhibitor administration used to enhance chemotherapy efficiency in a breast tumor xenograft model. J Magn Reson Imaging, 29, 1071-9 (2009)
41. Stroobants, S., J. Verschakelen & J. Vansteenkiste: Value of FDG-PET in the management of non-small cell lung cancer. Eur J Radiol, 45, 49-59 (2003) (Pubitemid 36020310)
42. Schueneman, A. J., E. Himmelfarb, L. Geng, J. Tan, E. Donnelly, D. Mendel, G. McMahon & D. E. Hallahan: SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res, 63, 4009-16 (2003) (Pubitemid 36917920)
43. Miller, T. W., J. T. Forbes, C. Shah, S. K. Wyatt, H. C. Manning, M. G. Olivares, V. Sanchez, T. C. Dugger, N. de Matos Granja, A. Narasanna, R. S. Cook, J. P. Kennedy, C. W. Lindsley & C. L. Arteaga: Inhibition of mammalian target of rapamycin is required for optimal antitumor effect of HER2 inhibitors against HER2-overexpressing cancer cells. Clin Cancer Res, 15, 7266-76 (2009)
44. Peterson, T. E. & H. C. Manning: Molecular imaging: 18F-FDG PET and a whole lot more. J Nucl Med Technol, 37, 151-61 (2009)
45. Manning, H. C., N. B. Merchant, A. C. Foutch, J. M. Virostko, S. K. Wyatt, C. Shah, E. T. McKinley, J. Xie, N. J. Mutic, M. K. Washington, B. LaFleur, M. N. Tantawy, T. E. Peterson, M. S. Ansari, R. M. Baldwin, M. L. Rothenberg, D. J. Bornhop, J. C. Gore & R. J. Coffey: Molecular imaging of therapeutic response to epidermal growth factor receptor blockade in colorectal cancer. Clin Cancer Res, 14, 7413-22 (2008)
46. Dubois, L.: Noninvasive imaging of hypoxia, hypoxia response and drug delivery: A bridge towards individualizedpatient treatment. Radiation Oncology, Maastricht University, 231 (2010)
47. Busk, M., M. R. Horsman, S. Jakobsen, K. V. Hansen, J. Bussink, A. van der Kogel & J. Overgaard: Can hypoxia-PET map hypoxic cell density heterogeneity accurately in an animal tumor model at a clinically obtainable image contrast? Radiother Oncol, 92, 429-36 (2009)
48. De Saint-Hubert, M., K. Prinsen, L. Mortelmans, A. Verbruggen & F. M. Mottaghy: Molecular imaging of cell death. Methods, 48, 178-87 (2009)
49. Moasser, M. M., L. J. Wilmes, C. H. Wong, S. Aliu, K. L. Li, D. Wang, Y. K. Hom, B. Hann & N. M. Hylton: Improved tumor vascular function following high-dose epidermal growth factor receptor tyrosine kinase inhibitor therapy. J Magn Reson Imaging, 26, 1618-25 (2007) (Pubitemid 350291291)
50. Ali, M. M., B. Janic, A. Babajani-Feremi, N. R. Varma, A. S. Iskander, J. Anagli & A. S. Arbab: Changes in vascular permeability and expression of different angiogenic factors following anti-angiogenic treatment in rat glioma. PLoS One, 5, e8727 (2010)
51. Gelovani, J. G.: Molecular imaging of epidermal growth factor receptor expression-activity at the kinase level in tumors with positron emission tomography. Cancer Metastasis Rev, 27, 645-53 (2008)
52. Blankenberg, F. G.: Imaging the molecular signatures of apoptosis and injury with radiolabeled annexin V. Proc Am Thorac Soc, 6, 469-76 (2009)
53. Tyas, L., V. A. Brophy, A. Pope, A. J. Rivett & J. M. Tavaréa: Rapid caspase-3 activation during apoptosis revealed using fluorescence- resonance energy transfer. EMBO Reports, 1, 266-270 (2000)
54. Lee, H., W. J. Akers, P. P. Cheney, W. B. Edwards, K. Liang, J. P. Culver & S. Achilefu: Complementary optical and nuclear imaging of caspase-3 activity using combined activatable and radio-labeled multimodality molecular probe. Journal of Biomedical Optics, 14, 040507-1 - 040507-3 (2009)
55. Zhou, D., W. Chu, J. Rothfuss, C. Zeng, J. Xu, L. Jones, M. J. Welch & R. H. Mach: Synthesis, radiolabeling, and in vivo evaluation of an 18F-labeled isatin analog for imaging caspase-3 activation in apoptosis Bioorganic and Medicinal Chermistry Letters, 16, 5041-5046 (2006) (Pubitemid 44247712)
56. Ray, P., A. De, M. Patel & S. S. Gambhir: Monitoring caspase-3 activation with a multimodality imaging sensor in living subjects. Clin Cancer Res, 14, 5801-9 (2008)
57. Gross, S. & D. Piwnica-Worms: Spying on cancer: molecular imaging in vivo with genetically encoded reporters. Cancer Cell, 7, 5-15 (2005) (Pubitemid 40126378)
58. Laakkonen, P., M. E. Akerman, H. Biliran, M. Yang, F. Ferrer, T. Karpanen, R. M. Hoffman & E. Ruoslahti: Antitumor activity of a homing peptide that targets tumor lymphatics and tumor cells. Proc Natl Acad Sci U S A, 101, 9381-6 (2004) (Pubitemid 38812883)
59. Lee, S. M., E. J. Lee, H. Y. Hong, M. K. Kwon, T. H. Kwon, J. Y. Choi, R. W. Park, T. G. Kwon, E. S. Yoo, G. S. Yoon, I. S. Kim, E. Ruoslahti & B. H. Lee: Targeting bladder tumor cells in vivo and in the urine with a peptide identified by phage display. Mol Cancer Res, 5, 11-9 (2007)
60. Trepel, M., W. Arap & R. Pasqualini: In vivo phage display and vascular heterogeneity: implications for targeted medicine. Curr Opin Chem Biol, 6, 399-404 (2002) (Pubitemid 34522068)
61. Han, Z., A. Fu, H. Wang, R. Diaz, L. Geng, H. Onishko & D. E. Hallahan: Noninvasive assessment of cancer response to therapy. Nat Med, 14, 343-9 (2008) (Pubitemid 351347907)
62. Faivre, S., G. Demetri, W. Sargent & E. Raymond: Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov, 6, 734-45 (2007) (Pubitemid 47338181)